arrow
A

Alessandro Cellini

University of Padua
H指数:7
被引数:156

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study

更正:携带t(14;19)易位的慢性淋巴细胞白血病患者临床和转录组学特征:一项ERIC研究

Leukemia
IF13.4
2026-10-160
OAAI
Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience

平衡老年(>70岁)滤泡性淋巴瘤患者接受 Bendamustine 联合抗CD20方案的安全性与有效性:一家三级学术中心的经验

2026-02-050
OAAI
An Uncommon Localization of Hairy Cell Leukemia: Central Nervous System Involvement and Response to Ibrutinib—A Case Report and a Review of the Literature

毛细胞白血病的不常见定位:中枢神经系统受累及伊布替尼的治疗反应——病例报告及文献综述

2025-10-310
OAAI
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病中中枢神经系统受累:ERIC(欧洲慢性淋巴细胞白血病研究倡议)国际回顾性研究

2025-10-280
OAAI
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study

携带t(14;19)易位的慢性淋巴细胞白血病患者临床及转录组学特征:一项ERIC研究

Leukemia
IF13.4
2025-09-190
OAAI
Serum soluble interleukin-2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring

毛细胞白血病中血清可溶性白细胞介素-2受体水平作为肿瘤负荷标志物,具有预后价值,并作为疾病监测工具。

2025-07-290
OAAI
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes

慢性淋巴细胞白血病患者接受伊布替尼治疗的弥漫性大b细胞淋巴瘤的Richter转化: 危险因素和结果

Leukemia
IF13.4
2025-06-250
OAAI
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort

基于维奈克拉茨方案的八旬慢性淋巴细胞白血病患者:疗效、安全性及与BTKi的比较(多中心队列研究)

2025-04-240
OA
Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD

经典霍奇金淋巴瘤的基线预后预测因素: PET/CT引导下ABVD治疗患者的回顾性单中心分析

2024-09-050
OAAI
Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy
2024-05-140
OAAI
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study
2023-06-292
OA
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies

Tixagevimab/Cilgavimab作为血液系统恶性肿瘤患者SARS-CoV-2的暴露前预防

2023-06-228
OAAI